Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) also making a luring appeal, share price swings at $0.53 with percentage change of 7.83% in most recent trading session. Tonix Pharmaceuticals Holding Corp. (TNXP), which is developing a next-generation treatment for PTSD, reported recently that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TNX-102 SL* for the treatment of posttraumatic stress disorder (PTSD).
“We are very pleased that the FDA has granted Breakthrough Therapy designation to TNX-102 SL for PTSD,” stated Seth Lederman, M.D., president & chief executive officer of Tonix. “This decision reflects the FDA’s recognition that PTSD is a serious disease, and that preliminary clinical evidence from our Phase 2 AtEase study in military-related PTSD supports TNX-102 SL’s potential advantage over currently-accessible PTSD therapies. In addition to being Phase 3-ready, the timeline for the manufacturing of commercial product to support a Breakthrough Therapy application aligns with our TNX-102 SL registration plan.”
While returns on assets calculated as -125.50% hat gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of -143.40%, which is measuring a corporation’s profitability by revealing how much profit generates by TNXP with the shareholders’ money. The firm attains analyst recommendation of 2.70 on scale of 1-5 with week’s performance of -8.04%.
Moving toward ratio analysis, it has current ratio of 11.20 and quick ratio was calculated as 11.20. The debt to equity ratio appeared as 0.00 for seeing its liquidity position. The firm attains analyst recommendation of 2.70 out of 1-5 scale with week’s performance of -8.04%.
Moving on tracing line, ImmunoGen, Inc. (NASDAQ:IMGN) need to consider for profitability analysis, in latest session share price swings at $1.62 with percentage change of -1.22%.
The returns on assets were -63.30% that gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of 237.30%, which is measuring profitability by disclosing how much profit generates by IMGN with the shareholders’ money.
The firm attains analyst recommendation of 2.40 on scale of 1-5 with week’s performance of -2.96%. The firm current ratio calculated as 3.70, this value is acceptable if it lies in 1.3% to 3%. But its varies industry to industry. To strengthen these views, active industry firm has Quick Ratio of 3.70, which indicates firm has sufficient short-term assets to cover its immediate liabilities.